Literature DB >> 18321980

Distinct ex vivo susceptibility of B-cell subsets to epstein-barr virus infection according to differentiation status and tissue origin.

Marcus Dorner1, Franziska Zucol, Christoph Berger, Rahel Byland, Gregory T Melroe, Michele Bernasconi, Roberto F Speck, David Nadal.   

Abstract

Epstein-Barr virus (EBV) uses tonsils as the portal of entry to establish persistent infection. EBV is found in various B-cell subsets in tonsils but exclusively in memory B cells in peripheral blood. The in vitro susceptibilities of B-cell subsets to EBV infection have been studied solely qualitatively. In this work, we examined quantitatively the in vitro susceptibilities of various B-cell subsets from different tissue origins to EBV infection. First, we established a centrifugation-based inoculation protocol (spinoculation) that resulted in a significantly increased proportion of infected cells compared to that obtained by conventional inoculation, enabling a detailed susceptibility analysis. Importantly, B-cell infection occurred via the known EBV receptors and infected cells showed EBV mRNA expression patterns similar to those observed after conventional inoculation, validating our approach. Tonsillar naïve and memory B cells were infected ex vivo at similar frequencies. In contrast, memory B cells from blood, which represent B cells from various lymphoid tissues, were infected at lower frequencies than their naïve counterparts. Immunoglobulin A (IgA)-positive or IgG-positive tonsillar memory B cells were significantly more susceptible to EBV infection than IgM-positive counterparts. Memory B cells were transformed with lower efficiency than naïve B cells. This result was paralleled by lower proliferation rates. In summary, these data suggest that EBV exploits the B-cell differentiation status and tissue origin to establish persistent infection.

Entities:  

Mesh:

Year:  2008        PMID: 18321980      PMCID: PMC2293034          DOI: 10.1128/JVI.02630-07

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

Review 1.  Epstein-Barr virus infection.

Authors:  J I Cohen
Journal:  N Engl J Med       Date:  2000-08-17       Impact factor: 91.245

2.  The dispersal of mucosal memory B cells: evidence from persistent EBV infection.

Authors:  Lauri L Laichalk; Donna Hochberg; Gregory J Babcock; Richard B Freeman; David A Thorley-Lawson
Journal:  Immunity       Date:  2002-05       Impact factor: 31.745

3.  Factor(s) required by EBV transformed lymphocytes to grow under limiting dilution conditions.

Authors:  C Negri; R Chiesa; G C Ricotti
Journal:  Cytotechnology       Date:  1991-11       Impact factor: 2.058

Review 4.  The origins of DNA breaks: a consequence of DNA damage, DNA repair, or apoptosis?

Authors:  A Eastman; M A Barry
Journal:  Cancer Invest       Date:  1992       Impact factor: 2.176

5.  Transcription of the Epstein-Barr virus genome during latency in growth-transformed lymphocytes.

Authors:  J Sample; E Kieff
Journal:  J Virol       Date:  1990-04       Impact factor: 5.103

6.  Isolation of a normal B cell subset with a Burkitt-like phenotype and transformation in vitro with Epstein-Barr virus.

Authors:  C D Gregory; C F Edwards; A Milner; J Wiels; M Lipinski; M Rowe; T Tursz; A B Rickinson
Journal:  Int J Cancer       Date:  1988-08-15       Impact factor: 7.396

7.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

8.  Human tonsillar tissue block cultures differ from autologous tonsillar cell suspension cultures in lymphocyte subset activation and cytokine gene expression.

Authors:  Bettina Giger; Athos Bonanomi; Bernhard Odermatt; Kristin Ladell; Roberto F Speck; Dejan Kojic; Christoph Berger; Felix K Niggli; David Nadal
Journal:  J Immunol Methods       Date:  2004-06       Impact factor: 2.303

9.  Infection of B lymphocytes by a human herpesvirus, Epstein-Barr virus, is blocked by calmodulin antagonists.

Authors:  G R Nemerow; N R Cooper
Journal:  Proc Natl Acad Sci U S A       Date:  1984-08       Impact factor: 11.205

10.  Immunoglobulin expression by human B lymphocytes clonally transformed by Epstein Barr virus.

Authors:  N A Brown; G Miller
Journal:  J Immunol       Date:  1982-01       Impact factor: 5.422

View more
  16 in total

1.  Plasma cell toll-like receptor (TLR) expression differs from that of B cells, and plasma cell TLR triggering enhances immunoglobulin production.

Authors:  Marcus Dorner; Simone Brandt; Marianne Tinguely; Franziska Zucol; Jean-Pierre Bourquin; Ludwig Zauner; Christoph Berger; Michele Bernasconi; Roberto F Speck; David Nadal
Journal:  Immunology       Date:  2009-12       Impact factor: 7.397

2.  Secondary NAD+ deficiency in the inherited defect of glutamine synthetase.

Authors:  Liyan Hu; Khalid Ibrahim; Martin Stucki; Michele Frapolli; Noora Shahbeck; Farrukh A Chaudhry; Boris Görg; Dieter Häussinger; W Todd Penberthy; Tawfeg Ben-Omran; Johannes Häberle
Journal:  J Inherit Metab Dis       Date:  2015-04-21       Impact factor: 4.982

3.  EBV microRNA-BHRF1-2-5p targets the 3'UTR of immune checkpoint ligands PD-L1 and PD-L2.

Authors:  Alexandre S Cristino; Jamie Nourse; Rachael A West; Muhammed Bilal Sabdia; Soi C Law; Jay Gunawardana; Frank Vari; Sally Mujaj; Gayathri Thillaiyampalam; Cameron Snell; Madeline Gough; Colm Keane; Maher K Gandhi
Journal:  Blood       Date:  2019-12-19       Impact factor: 22.113

4.  beta1 integrin expression increases susceptibility of memory B cells to Epstein-Barr virus infection.

Authors:  Marcus Dorner; Franziska Zucol; Davide Alessi; Stephan K Haerle; Walter Bossart; Markus Weber; Rahel Byland; Michele Bernasconi; Christoph Berger; Sharof Tugizov; Roberto F Speck; David Nadal
Journal:  J Virol       Date:  2010-04-28       Impact factor: 5.103

5.  Toll-like receptor agonists synergistically increase proliferation and activation of B cells by epstein-barr virus.

Authors:  Stefanie Iskra; Markus Kalla; Henri-Jacques Delecluse; Wolfgang Hammerschmidt; Andreas Moosmann
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

6.  Coinfection with EBV/CMV and other respiratory agents in children with suspected infectious mononucleosis.

Authors:  Xia Wang; Kun Yang; Cong Wei; Yuan Huang; Dongchi Zhao
Journal:  Virol J       Date:  2010-09-21       Impact factor: 4.099

7.  Gene expression profiling of the response to interferon beta in Epstein-Barr-transformed and primary B cells of patients with multiple sclerosis.

Authors:  Rana Khsheibun; Tamar Paperna; Anat Volkowich; Izabella Lejbkowicz; Nili Avidan; Ariel Miller
Journal:  PLoS One       Date:  2014-07-15       Impact factor: 3.240

8.  Telomerase activity impacts on Epstein-Barr virus infection of AGS cells.

Authors:  Jürgen Rac; Florian Haas; Andrina Schumacher; Jaap M Middeldorp; Henri-Jacques Delecluse; Roberto F Speck; Michele Bernasconi; David Nadal
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

9.  Unexpected patterns of Epstein-Barr virus transcription revealed by a high throughput PCR array for absolute quantification of viral mRNA.

Authors:  Rosemary J Tierney; Claire D Shannon-Lowe; Leah Fitzsimmons; Andrew I Bell; Martin Rowe
Journal:  Virology       Date:  2014-11-15       Impact factor: 3.616

10.  Epstein-Barr virus infection of naïve B cells in vitro frequently selects clones with mutated immunoglobulin genotypes: implications for virus biology.

Authors:  Emily Heath; Noelia Begue-Pastor; Sridhar Chaganti; Debbie Croom-Carter; Claire Shannon-Lowe; Dieter Kube; Regina Feederle; Henri-Jacques Delecluse; Alan B Rickinson; Andrew I Bell
Journal:  PLoS Pathog       Date:  2012-05-10       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.